Lasa Supergenerics Ltd. appears to be significantly underperforming compared to its peers in the pharmaceuticals industry, with no revenue growth, negative PE, and lack of profitability metrics. This positions it as a laggard in the sector, highlighting potential risks for investors.

• • Lasa Supergenerics Ltd. shows no growth and negative profitability metrics.
• • Top performers like Sun Pharmaceutical and Dr. Reddy's exhibit strong revenue growth and profitability.
• • Lasa is financially weak with no returns and a debt-equity ratio of 0.